Cumberland Partners Ltd Buys Shares of 76,600 Pfizer Inc. (NYSE:PFE)

Cumberland Partners Ltd acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 76,600 shares of the biopharmaceutical company's stock, valued at approximately $2,032,000.

A number of other large investors have also added to or reduced their stakes in PFE. Swedbank AB boosted its stake in Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company's stock worth $166,284,000 after purchasing an additional 37,636 shares in the last quarter. Copeland Capital Management LLC purchased a new position in Pfizer in the third quarter worth about $144,000. Sequoia Financial Advisors LLC lifted its stake in shares of Pfizer by 55.9% in the third quarter. Sequoia Financial Advisors LLC now owns 422,143 shares of the biopharmaceutical company's stock worth $12,217,000 after buying an additional 151,293 shares in the last quarter. Eastern Bank grew its holdings in shares of Pfizer by 481.4% during the third quarter. Eastern Bank now owns 107,466 shares of the biopharmaceutical company's stock valued at $3,110,000 after buying an additional 88,982 shares during the last quarter. Finally, Symphony Financial Ltd. Co. increased its position in shares of Pfizer by 19.1% during the third quarter. Symphony Financial Ltd. Co. now owns 41,106 shares of the biopharmaceutical company's stock valued at $1,181,000 after acquiring an additional 6,586 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.06% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several analyst reports. Evercore ISI raised Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Guggenheim restated a "buy" rating and issued a $33.00 target price on shares of Pfizer in a report on Monday, February 10th. Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Finally, StockNews.com downgraded Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.53 during midday trading on Friday, reaching $26.43. The stock had a trading volume of 39,866,963 shares, compared to its average volume of 38,022,176. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The stock has a 50-day moving average of $26.28 and a 200-day moving average of $27.44. The company has a market capitalization of $149.76 billion, a price-to-earnings ratio of 18.71, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same period last year, the firm earned $0.10 earnings per share. The business's quarterly revenue was up 24.7% on a year-over-year basis. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.51%. This is an increase from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer's dividend payout ratio is presently 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.